Xeltis secures nearly €50m to advance aXess, its vascular access conduit, from the EIB and existing shareholders.
PRIVATEDec 02, 2025
Amount Raised
€50 Million
Round Type
Funding Round
EindhovenManufacturingBiotechnologyHealth Care
Investors
Invest NlEQTEuropean Investment Bank
Description
Xeltis has secured nearly €50m in financing, including €37.5m from the EIB and €10m from existing investors like EQT. This funding will support the commercialization of aXess, enhancing production and workforce. The investment follows promising clinical trial results for the product. Xeltis is set to advance towards bringing this innovative treatment to market.
Who to call at Xeltis, and when
A new round usually means Xeltis is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Xeltis raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Xeltis, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Xeltis
Location
Eindhoven, North Brabant, Netherlands
About
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. The Company seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. Xeltis' proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient's own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Xeltis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
EindhovenManufacturingBiotechnologyHealth Care